Comparative Pharmacology
Head-to-head clinical analysis: RAZADYNE versus RIVASTIGMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAZADYNE versus RIVASTIGMINE.
RAZADYNE vs RIVASTIGMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Galantamine is a reversible competitive acetylcholinesterase inhibitor and an allosteric modulator of nicotinic acetylcholine receptors, enhancing cholinergic function in the central nervous system.
Reversible acetylcholinesterase inhibitor that enhances cholinergic function by increasing the concentration of acetylcholine at synaptic sites. Also inhibits butyrylcholinesterase.
Initial dose 8 mg/day PO (4 mg twice daily) for 4 weeks; increase to 16 mg/day (8 mg twice daily) for at least 4 weeks; maintenance 16-24 mg/day (12 mg twice daily). Extended-release: initial 8 mg PO once daily; after 4 weeks increase to 16 mg once daily; if tolerated, may increase to 24 mg once daily.
1.5 mg orally twice daily initially, titrated by 1.5 mg/dose every 2 weeks to maintenance dose of 3-6 mg twice daily. Alternatively, transdermal patch: 4.6 mg/24h initially, titrate to 9.5 mg/24h after 4 weeks, then 13.3 mg/24h if tolerated.
None Documented
None Documented
Clinical Note
moderateRivastigmine + Dronedarone
"Rivastigmine may increase the bradycardic activities of Dronedarone."
Clinical Note
moderateRivastigmine + Nicotine
"The risk or severity of adverse effects can be increased when Rivastigmine is combined with Nicotine."
Clinical Note
moderateRivastigmine + Amiodarone
"Rivastigmine may increase the bradycardic activities of Amiodarone."
Clinical Note
moderateRivastigmine + Crizotinib
Terminal elimination half-life is approximately 7-8 hours in healthy adults, allowing twice-daily dosing; unchanged in mild to moderate hepatic impairment but prolonged in severe hepatic impairment.
Terminal half-life ~1.5 h (oral, transdermal); clinical context: due to prolonged binding to acetylcholinesterase (AChE), effective half-life for AChE inhibition is ~10 h; steady state reached in 6-12 weeks.
Renal excretion of unchanged drug accounts for approximately 20-25% of the dose; the remainder is metabolized by the liver and excreted as metabolites in urine (about 95% total) and feces (about 5%).
Renal: ~97% total (mostly metabolites, <1% unchanged); fecal: negligible; biliary: minor.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor
"Rivastigmine may increase the bradycardic activities of Crizotinib."